Get the Stockscreener App
1.18
3.28%
-0.04
After Hours:
1.18
Dermata Therapeutics Inc stock is traded at $1.18, with a volume of 63,805.
It is down -3.28% in the last 24 hours and up +4.42% over the past month.
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.
See More
Previous Close:
$1.22
Open:
$1.21
24h Volume:
63,805
Relative Volume:
0.14
Market Cap:
$6.32M
Revenue:
-
Net Income/Loss:
$-11.27M
P/E Ratio:
-0.0551
EPS:
-21.4132
Net Cash Flow:
$-9.40M
1W Performance:
-2.48%
1M Performance:
+4.42%
6M Performance:
-25.32%
1Y Performance:
-80.61%
1-Day Range:
$1.17
$1.24
1-Week Range:
$1.17
$1.29
52-Week Range:
$1.00
$6.666
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
(858)-223-0882
Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
1.18 | 6.32M | 0 | -11.27M | -9.40M | -21.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Dermata Therapeutics Inc Stock (DRMA) Latest News
Stocks Rally as US Consumer Prices Cool - The Globe and Mail
Acne Market on Track for Major Expansion by 2032, According to DelveInsight | Clinuvel Pharma, Novan, Dermata Therapeutics, ioPharmX, Bausch Health Americas, Inc., Kintor Pharma, Sol-Gel Technologies - Barchart
Acne Market on Track for Major Expansion by 2032, According - openPR
Severe Acne Vulgaris or Severe Recalcitrant Nodular Acne - openPR
Tesla Stock is OversoldIs Now the Time to Be Brave? - The Globe and Mail
Geron (NASDAQ:GERN) versus Dermata Therapeutics (NASDAQ:DRMA) Head-To-Head Comparison - Defense World
Dermata Announces That Last Patient Completes Last Visit In Pivotal Xyngari Phase 3 Star-1 Clinical Trial For Acne - Marketscreener.com
Dermata Therapeutics announces last patient visit in Phase 3 acne trial - TipRanks
Can Dermata's Once-Weekly Acne Treatment Disrupt a 30M-Patient Market? - StockTitan
Acne Market Predicted to See Upsurge Through 2032, Highlights - openPR
Papulopustular Rosacea Clinical and Non-Clinical Studies, Key - openPR
APO accepts Dermata’s patent application for DMT410 program for hyperhidrosis - MSN
Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga
DRMADermata Therapeutics Inc Latest Stock News & Market Updates - StockTitan
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Botulinum Toxin Treatment for Hyperhidrosis - ACCESS Newswire
Can Dermata's Needle-Free Botox Alternative Transform Excessive Sweating Treatment? - StockTitan
Dermata Therapeutics announces $2.55M private offering - MSN
Dermata Therapeutics Announces $2.55 Million Private Placement Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire
Crown Labs completes acquisition of Revance Therapeutics By Investing.com - Investing.com Nigeria
Crown Labs completes acquisition of Revance Therapeutics - Investing.com India
Dermata to Present on BioPub on January 31, 2025 - ACCESS Newswire
Dermata Unveils Game-Changing Skin Disease Treatment Progress: CEO Reveals What's Next - StockTitan
Acne Vulgaris Market Expected to rise, 2034 | Pelthos - openPR
Dermata Expands Patent Portfolio with Issuance of New U.S. Patent for Next-Generation Acne Treatment - ACCESS Newswire
Dermata Therapeutics Signs Clinical Trial Collaboration Agreement with Revance Therapeutics for Topical Treatment StudyDermata Therapeutics, Inc. (NASDAQ: DRMA) revealed in an 8-K filing that on January 17, 2025, the company entered into a Clinical T - Defense World
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024 - ACCESS Newswire
Dermata Therapeutics Announces Private Placement of $2.4 Million in Securities SAN DIEGO, CA – Dermata Therapeutics, Inc. (NASDAQ: DRMA) disclosed in a filing on January 21, 2025, that it has entered into a securities purchase agreement for a private - Defense World
Dermata Receives Notice of Allowance for New U.S. Patent for DMT310 for the Treatment of Acne - ACCESS Newswire
Dermata Therapeutics Announces $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire
Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering - ACCESS Newswire
Dermata Completes Enrollment in First Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne - ACCESS Newswire
Biotech Alert: Searches spiking for these stocks today - TipRanks
Dermata Therapeutics secures $2.55 million in private placement - MSN
Dermata Therapeutics Announces Closing of $3.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules - ACCESS Newswire
Dermata Therapeutics, Inc. announced that it has received $2.550008 million in funding -January 22, 2025 - Marketscreener.com
Dermata Therapeutics Secures $2.55M Private Placement with Strong Insider Participation - StockTitan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Dermata, Revance test new hyperhidrosis treatment By Investing.com - Investing.com Australia
Dermata, Revance test new hyperhidrosis treatment - MSN
Dermata and Revance Partner on First Needle-Free Botulinum Treatment for Excessive Sweating - StockTitan
Acne Vulgaris Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | Dermata Therapeutics, AstraZeneca, Novartis, UCB Pharma, Incyte Inc., Galderma - The Globe and Mail
Accenture Plc (ACN-N) QuotePress Release - The Globe and Mail
Dermata Therapeutics Inc (DRMA): Major Improvements, Worth A Look - Stocks Register
Dermata Therapeutics (NASDAQ:DRMA) Trading Up 1.2% – Still a Buy? - Defense World
Dermata Therapeutics, Inc. Receives Approval from FDA for the Proprietary Name Xyngarifor for Its Phase 3 Clinical Drug Candidate in Acne - Marketscreener.com
Dermata Receives Approval from FDA for the Proprietary Name Xyngari(TM) - AccessWire
Dermata's Acne Treatment 'Xyngari' Secures FDA Name Approval; Phase 3 Data Expected March 2025 - StockTitan
Dermata Therapeutics stock hits 52-week low at $1.05 By Investing.com - Investing.com UK
Dermata Secures Key Patent for Revolutionary Acne Treatment DMT310 Ahead of Phase 3 Results - StockTitan
The Best Warren Buffett Stocks to Buy With $500 Right Now - The Globe and Mail
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):